Abstract
Curcumin, a yellow pigment from Curcuma longa, is a major component of turmeric and is commonly used as a spice and food-coloring agent. It is also used as a cosmetic and in some medical preparations. The desirable preventive or putative therapeutic properties of curcumin have also been considered to be associated with its antioxidant and anti-inflammatory properties. Because free-radical-mediated peroxidation of membrane lipids and oxidative damage of DNAand proteins are believed to be associated with a variety of chronic pathological complications such as cancer, atherosclerosis, and neurodegenerative diseases, curcumin is thought to play a vital role against these pathological conditions.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
References
1. A. Mukhopadhyay, N. Basu, N. Ghatak, and P. K. Gujral, Antiinflammatory and irritant activities of curcumin analogues in rats. Agents Actions 12, 508–515 (1982).
2. A. C. Reddy and B. R. Lokesh, Effect of dietary turmeric (Curcuma longa) on iron induced lipid peroxidation in the rat liver. Food Chem Toxicol 32, 279–283 (1994).
3. R. A. Sharma, A. J. Gescher, and W. P. Steward, Curcumin: The story so far. Eur J Cancer 41, 1955–1968 (2005).
4. C. Kalpana, K. N. Rajasekharan, and V. P. Menon, Modulatory effects of curcumin and curcumin analog on circulatory lipid profiles during nicotine-induced toxicity in Wistar rats. J Med Food 8(2), 246–250 (2005).
5. A. R. Sudheer, C. Kapana, M. Srinivasan, and V P. Menon, Ferulic acid modulates altered lipid profiles and prooxidant/antioxidant status in circulation during nicotine-induced toxicity: A dose-dependent study. Toxicol Mech Methods 15, 1–7 (2005).
6. D. Harman, Aging: A theory based on free radical and radiation chemistry. J Gerentol 2, 298–300 (1956).
7. A. P. Arrigo, Gene expression and thiol redox state. Free Radical Biol Med 27, 936–944 (1983).
8. J. J. Hadad, Antioxidant and prooxidant mechanisms in the regulation of redox (Y)—sensitive factors. Cell Signal 14, 879–897 (1989).
9. B. Halliwell and J. M. C. Gutteridge, Free Radicals in Biology and Medicine. Oxford University Press, Oxford, 1989, p. 63
10. J. J. Poderoso, M. C. Carreras, C. Lisdero, N. Riobo, F. Schopfer, and A. Boveris, Nitric oxide inhibits electron transfer and increases superoxide radical production in rat heart mitochondria and submitochondrial particles. Arch Biochem Biophys 328, 85–92 (1996).
11. B. Halliwell and J. M. C. Gutteridge, Antioxidant defenses. In: Free Radicals in Biology and Medicine, 3rd ed. Oxford University Press, Oxford, 1999, pp. 105–245.
12. B. Wood and A. Brooks, Human evolution: We are what we ate. Nature 400, 219–220 (1990).
13. J. S. Wright, Predicting the antioxidant activity of curcumin and curcuminoids. J Mol Struct (Theochem) 591, 207–217 (2002).
14. S. V. Jovanovic, S. Steenken, C. W. Boone, and M. G. Simic, H-atom transfer is a preferred antioxidant mechanism of curcumin. J Am Chem Soc 121, 9677–9681 (1999).
15. L. R. C. Barclay, M. R. Vinqvist, K. Mukai, H. Goto, Y. Hashimoto, A. Tokuanga, and H. Uno, The antioxidant mechanism of curcumin: Classical methods are needed to determine antioxidant mechanism and activity. Org Lett 2, 2841–2843 (2000).
16. K. I. Priyadarsini, D. K. Maity, G. H. Naik, M. S. Kumar, M. K. Unnikrishnan, J. G. Satav, and H. Mohan, Role of phenolic O:H and methylene hydrogen on the free radical reaction and antioxidant activity of curcumin. Free Radical. Biol Med 35, 475–484 (2003).
17. Y. M. Sun, H. Y. Zhang, D. Z. Chen, and C. B. Liu, Theoretical elucidation on the antioxidant mechanism of curcumin: A DFT study. Org Lett 4, 2909–2911 (2002).
18. L. Shen, H. Y. Zhang, and H. F. Ji, Successful application of TD-DFT in transient absorption spectra assignment. Org Lett 7, 243–246 (2005).
19. G. Litwinienko and K. U. Ingold, Abnormal solvent effect on hydrogen atom abstraction: Resolution of the curcumin antioxidant controversy. The role of sequential proton loss electron transfer. J Org Chem 64, 5888–5896 (2004).
20. M. T. Huang, T. Lysz, T. Ferraro, T. F. Abidi, J. D. Laskin, and A. H. Conney, Inhibitory effects of curcumin on in vitro lipoxygenase and cyclooxygenase activities in mouse epidermis. Cancer Res 51, 813–819 (1991).
21. L. Qiao, V. Kozoni, G. J. Tsioulias, M. I. Koutsos, R. Hanif, and S. J. Shiff, Selected eicosaniods increase the proliferation rate of human colon carcinoma cell lines and mouse colonocytes in vivo. Biochim Biophys Acta 1258, 215–223 (1995).
22. C. D. Funk, L. B. Funk, M. E. Kennedy, A. S. Pong, and G. A. FitzGerald, Human platelet/erythroleukemia cell prostaglandin G/H synthase:cDNA cloning, expression and gene chromosomal assignment. FASEB J 5, 2304–2312 (1991).
23. K. Subbaramaiah, N. Telang, J. T. Ramonetti, R. Araki, B. DeVito, B. B. Weksler, and A. J. Dannenberg, Transcription of cyclooxygenase-2 is enhanced in transformed mammary epithelial cells Cancer Res 56, 4424–4429 (1996).
24. H. Y. Fang, T. S. Lin, J. P. Lin, Y. C. Wu, K. C. Chow, and L. S. Wang, Cyclooxygenase-2 in human non-small cell lung cancer. Eur J Surg Oncol 29, 171–177 (2003).
25. J. L. Masferrer, B. S. Zweifel, P. T. Manning, S. D. Hauser, K. M. Leahy, W. G. Smith, P. C. Isakson, and K. Seibert, Selective inhibition of cyclooxygenase-2 in vivo is antiinflammatory and nonulcerogenic. Proc Natl Acad Sci USA 91, 3228–3232 (1994).
26. T. Kawamori, C. V. Rao, K. Seibert, and B. S. Reddy, Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res 58, 409–412 (1998).
27. F. Zhang, N. K. Altorki, J. R. Mestre, K. Subbaramaiah, and A. J. Dannenberg, Curcumin inhibits cyclooxygenase-2 transcription in bile acid- and phorbol ester-treated human gastrointestinal epithelial cells. Carcinogenesis 20, 445–451 (1999).
28. J. Hong, M. Bose, J. Ju, J. H. Ryu, X. Chen, and S. Sang, Modulation of arachidonic acid metabolism by curcumin and related beta-diketone derivatives: Effects on cytosolic phospholipase A(2), cyclooxygenases and 5-lipoxygenase. Carcinogenesis 25(9), 1671–1679 (2004).
29. A. Goel, C. R. Boland, and D. P. Chauhan, Specific inhibition of cyclooxygenase-2 (COX-2) expression by dietary curcumin in HT-29 human colon cancer cells. Cancer Lett 172,111–118 (2001)
30. Y. J. Surh, K. S. Chun, H. H. Cha, S. S. Han, Y. S. Keum, K. K. Park, and S. S. Lee, Molecular mechanisms underlying chemopreventive activities of anti-inflammatory phytochemicals: Down-regulation of COX-2 and iNOS through suppression of NF-kB activation. Mutat Res 480, 243–268 (2001).
31. K. Chin, Y. Kurashima, T. Ogura, H. Tajiri, S. Yoshida, and Esumi, Induction of vascular endothelial growth factor by nitric oxide in human glioblastoma and hepatocellular carcinoma cells. Oncogene 15, 437–442 (1997).
32. N. V. Blough and O. C. Zafiriou, Reaction of superoxide with nitric oxide to form peroxynitrite in alkaline aqueous solution. Inorg Chem 24(4), 3502–3505 (1995).
33. C. Szabo and H. Ohshima, DNA damage induced by peroxynitrite: subsequent biological effects. Nitric Oxide 1, 373–385 (1997).
34. Messmer U. K., M. Ankarcrona, P. Nicotera, and B. Brune, p53 expression in nitric oxide-induced apoptosis. FEBS Lett 355, 23–26 (1994).
35. S. R. Goldstein, G. Y. Yang, X. Chen, S. K. Curtis, and C. S. Yang, Studies of iron deposits, inducible nitric oxide synthase and nitrotyrosine in a rat model for esophageal adenocarcinoma. Carcinogenesis 19, 1445–1449 (1998).
36. L. L. Thomsen, D. W. Miles, L. Happerfield, L. G. Bobrow, R. G. Knowles, and S. Moncada, Nitric oxide synthase activity in human breast cancer. Br J Cancer 72, 41–44 (1995).
37. M. Takahashi, K. Fukuda, T. Ohata, and K. Wakabayashi, Increased expression of inducible and endothelial nitric oxide synthases in rat colon tumors induced by azoxymethane. Cancer Res 57, 1233–1237 (1997).
38. D. C. Jenkins, I. G. Charles, L. L. Thomsen, D. W. Moss, L. S. Holmes, S. A. Baylis, P. Rhodes, K. Westmore, P. C. Emson, and S. Moncada, Roles of nitric oxide in tumor growth. Proc Natl Acad Sci USA 92, 4392–4396 (1995).
39. L. M. Landino, B. C. Crews, M. D. Timmons, J. D. Morrow, and L. J. Marnett, Peroxynitrite, the coupling product of nitric oxide and superoxide, activates prostaglandin biosynthesis. Proc Natl Acad Sci USA 93, 15,069–15,074 (1996).
40. I. Brouet and H. Ohshima, Curcumin, an anti-tumor promoter and anti-inflammatory agent, inhibits induction of nitric oxide synthase in activated macrophages. Biochem Biophys Res Commun 206, 533–540 (1995).
41. M. M. Chan, H. I. Huang, M. R. Fenton, and D. Fong, In vivo inhibition of nitric oxide synthase gene expression by curcumin, a cancer preventive natural product with anti-inflammatory properties. Biochem Pharmacol 55, 1955–1962 (1998).
42. F. Chen, V. Castranova, X. Shi, and L. M. Demers, New insights into the role of nuclear factor-kB, a ubiquitous transcription factor in the initiation of diseases. Clin Chem 45, 7–17 (1999).
43. D. Gius, A. Botero, S. Shah, and H. A. Curry, Oxidation/reduction status in the regulation of transcription factors NF-kB and AP-1. Toxicol Lett 106, 93–106 (1999).
44. I. Luque and C. Gelinas, Rel/NF-kB and IkB factors in oncogenesis. Semin Cancer Biol 8, 103–111 (1997).
45. H. Jo, R. Zhang, T. A. McKinsey, J. Shao, R. D. Beauchap, D. W. Ballard, and P. Liang, NF-kB is required for H-ras oncogene-induced abnormal cell proliferation and tumorigenesis. Oncogene 19, 841–849 (2000).
46. S. Singh and B. B. Aggarwal, Activation of transcription factor NF-kB is suppressed by curcumin (diferuloylmethane). J Biol Chem 270, 24,995–25,000 (1995).
47. F. H. Sarkar and Y. Li, Cell signaling pathways altered by natural chemopreventive agents. Mutat Res 555, 53–64 (2004).
48. B. B. Aggarwal, Signalling pathways of the TNF superfamily: A double-edged sword. Nat Rev Immunol 3(9), 745–756 (2003).
49. R. J. Moore, D. M. Owens, G. Stamp, C. Arnott, F. Burke, N. East, H. Holdsworth, L. Turner, B. Rollins, M. Pasparakis, G. Kollias, and F. Balkwill, Mice deficient in tumor necrosis factor-alpha are resistant to skin carcinogenesis. Nature Med 5(7), 828–831 (1999).
50. B. J. Sugarman, B. B. Aggarwal, P. E. Hass, I. S. Figari, M. A. Palladino, Jr., and H. M. Shepard, Recombinant human tumor necrosis factor-alpha: Effects on proliferation of normal and transformed cells in vitro. Science 230(4728), 943–945 (1985).
51. S. Shishodia, H. M. Amin, R. Lai, and B. B. Aggarwal, Curcumin (diferuloylmethane) inhibits constitutive NF-kappaB activation, induces G1/S arrest, suppresses proliferation, and induces apoptosis in mantle cell lymphoma. Biochem Pharmacol 70(5), 700–713 (2005).
52. P. A. Cerutti, Prooxidant states and tumor promotion. Science 227, 375–381 (1985).
53. W. J. Kozumbo, M. A. Trush, and T. W. Kensler, Are free radicals invlolved in tumor promotion? Chem–Biol Interact 54, 199–207 (1985).
54. W. Troll and R. Wiesner, The role of oxygen free radicals as a possible mechanism of tumor promotion. Annu Rev Pharmacol Toxicol 25, 509–528 (1985).
55. E. M. Perchellet and J. P. Perchellet, Characterization of the hydroperoxide response observed in mouse skin treated with tumor promoters in vivo. Cancer Res 49, 6193–6201 (1989).
56. J. J. Pence and J. J. Reiners, Murine epidermal xanthine oxidase activity: Correlation with degree of hyperplasia induced by tumor promoters. Cancer Res 47, 6388–6392 (1987).
57. L. Srinivas, T. Gindhart, and N. H. Colburn, Tumor-promoter resistant cells lack trisialoganglioside response. Proc Natl Acad Sci USA 79, 4988–4991 (1982).
58. T. W. Kensler, D. M. Bush, and W. J. Kozumbo, Inhibition of tumor promotion by a biomimetic superoxide dismutase. Science 221, 75–77 (1983).
59. L. J. Marnett, Peroxy free radicals: potential mediators of tumor initiation and promotion. Carcinogenesis 8, 1365–1373 (1987).
60. A. K. Verma, C. L. Ashendel, and R K. Boutwell, Inhibition by prostaglandin synthesis inhibitors of the induction of epidermal ornithine decarboxylase activity, the accumulation of prostaglandins, and tumor promotion caused by 12-O-tetradecanoylphorbol-13-acetate. Cancer Res 40, 308–315 (1980).
61. M. Nagabhushan and S. V. Bhide, Curcumin as an inhibitors of cancer. J Am Coll Nutr 11, 192–198 (1992).
62. Y. P. Lu, R. L. Chang, M. T. Huang, and A. H. Conney, Inhibitory effects of topical application of low doses of curcumin on 12-O-tetradecanoylphorbol-13-acetate-induced increase in ornithine decarboxylase mRNA in mouse epidermis. Carcinogenesis 14, 293–297 (1993).
63. Y. J. Surh, K. K. Park, K. S. Chun, J. M. Lee, E. Lee, and S. S. Lee, Anti-tumor promoting activities of selected pungent substances present in ginger. J Environ Toxicol Pathol Oncol 18, 131–139 (1999).
64. M. T. Huang, W. Ma, P. Yen, J. G. Xie, J. Han, K. Frenkel, D. Grunberger, and A. H. Conney, Inhibitory effects of topical application of low doses of curcumin on 12-O-tetra-decanoylphorbol-13-acetate-induced tumor promotion and oxidized DNA bases in mouse epidermis. Carcinogenesis 18, 83–88 (1997).
65. Y. Nakamura, Y. Ohto, A. Murakami, T. Osawa, and H. Ohigashi, Inhibitory effects of curcumin and tetrahydrocurcuminoids on the tumor promoter-induced reactive oxygen species generation in leukocytes in vitro and in vivo. Jpn J Cancer Res 89, 361–370 (1998).
66. T. S. Huang, S. C. Lee, and J. K. Lin, Suppression of c-Jun/AP-1 activation by an inhibitor of tumor promotion in mouse fibroblast cells. Proc Natl Acad. Sci USA 88, 5292–5296 (1991).
67. S. Kilaru, S. G. Frangos, A. H. Chen, D. Gottler, A. Dhadwal, O. Araim, and B. E. Sumpio, Nicotine: A review of its role in atherosclerosis. J Am Coll Surg 193, 538–546 (2001).
68. R. Olszanecki, J. Jawien, M. Gajda, L. Mateuszuk, A. Gebska, M. Korabiowska, S. Chlopicki, and R. Korbut, Effect of curcumin on atherosclerosis in apoE/LDLR-double knockout mice. J Physiol Pharmacol 56(4), 627–635 (2005).
69. R. Srivastava, M. Dikshit, R. C. Srimal, and B. N. Dhawan, Anti-thrombotic effect of curcumin. Thromb Res 40(3), 413–417 (1985).
70. N. Toda, T. Okamura, I. Shimizu, and Y. Tatsuno, Postmortem functional changes in coronary and cerebral arteries from humans and monkeys. Cardiovasc Res 11, 707–713 (1985).
71. R. B. Arora, S. K. Gupta, R. C. Sharma, and H. H. Siddiqui, Isolation and characterization of a sodium retaining substance from pig heart muscle and its role in myocardial infarction. Indian J Med Res 59(3), 483–493 (1971).
72. S. Chandra, S. K. Mukherjee, and N. Sethi, Effect of argemone oil feeding on blood biochemistry and tissue changes in albino rats. Indian J Med Sci 26(5), 308–312 (1972).
73. R L. Saul, P. Gee, and B. N. Ames, Free radicals, DNA damage and aging. In: Modern Biological Theories of Aging, H. R. Warner (ed). Raven Press, New York, 1987.
74. D. Harman, Free radical theory of aging: Effect of free radical inhibitors on the mortality rate of male LAP mice, J Gerontol 23, 476–482 (1968).
75. D. Harman, The aging process. Proc Natl Acad Sci USA 78, 124–128 (1981).
76. J. M. Talmashoff, T. Ouo, and R. G. Cutter, Superoxide dismutase: Correlation with life-span and specific metabolic rate in primate species. Proc Natl Acad Sci USA 77, 2777–2781 (1980).
77. J. M. Ringman, S. A. Frautschy, G. M. Cole, D. L. Masterman, and J. L. Cummings, A potential role of the curry spice curcumin in Alzheimer's disease. Curr Alzheimer Res 22(2), 131–136 (2005).
78. M. Grundman, M. Grundman, and P. Delaney, Antioxidant strategies for Alzheimer's disease. Proc Nutr Soc. 61(2), 191–202 (2002).
79. R. C. Benyon and M. J. Arthur, Mechanisms of hepatic fibrosis. J. Pediatr Gastroenterol Nutr 27, 75–85 (1998).
80. A. D. Burt, Cellular and molecular aspects of hepatic fibrosis. J Pathol 170, 105–114 (1993).
81. H. Nagase and F. Woessner, Jr., Matrix metallo proteinases. J Biol Chem 274, 21,491–21, 494 (1999).
82. M. J. Arthur, Fibrogenesis II. Metalloproteinases and their inhibitors in liver fibrosis. Am J Physiol Gastrointest Liver Physiol 279(2), G245–G249 (2000).
83. G. Akila, V. Rajakrishnan, P. Viswanathan, K. N. Rajashekaran, and V. P. Menon, Effects of curcumin on lipid profile and lipid peroxidation status in experimental hepatic fibrosis. Hepatol Res 11,147–157 (1998).
84. R. Rukkumani, K. Aruna, P. S. Varma, and V. P. Menon, Curcumin influences hepatic expression patterns of matrix metalloproteinases in liver toxicity. Italian J Biochem 53, 61–66 (2004).
85. B. Tesfamariam, Free radicals in diabetic endothelial cell dysfunction. Free Radical Biol Med 16, 383–391 (1994).
86. A. Bierhaus, M. A. Hofmann, R. Ziegler, and P. Nawroth, AGE and other interaction with AGE-receptors in vascular disease and diabetes-I. The AGE concept. Cardiovasc Res 37, 586–590 (1998).
87. G. L. King, H. Ishii, and D. Koya, Diabetic vascular dysfunction: A model of excessive activation of protein kinase C. Kidney Int 60, S77–S85 (1997).
88. J. R. Williamson, K. Chang, M. Frangos, K. S. Hasan, Y. Ido, T. Kawamura, J. R. Nyengaard, M. Van Den Enden, C. Kilo, and R. G. Tilton, Hyperglycemic pseudohypoxia and diabetic complications. Diabetes 42, 801–813 (1993).
89. B. Goossens, J. Grooten, K. De Vos, and W. Fiers, Direct evidence for tumor necrosis factor-induced mitochondrial reactive oxygen intermediates and their involvement in cytotoxicity. Proc Natl Acad Sci USA 92(18), 8115–8119 (1995).
90. G. Boden, Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes 46(1), 3–10 (1997).
91. C. R. Kahn, Causes of insulin resistance. Nature 373(6513), 384–385 (1995).
92. G. B. Sijitlal, P. Chitra, and G. Chandrakasan, Effect of curcumin on the advanced glycation and cross-linking of collagen in diabetic rats. Biochem Pharmacol 56(12), 1067–1074 (1998).
93. T. Mahesh, M. Sri Balasubashini, and V. P. Menon, Photo irradiated curcumin supplementation in streptozotocin-induced diabetic rats: Effect on lipid peroxidation. Therapie 59(6), 639–644 (2004).
94. C. J. Li, L. J. Zhang, B. J. Dezube, C. S. Crumpacker, and A. B. Pardee, Three inhibitors of type 1 human immunodeficiency virus long terminal repeat-directed gene expression and virus replication. Proc Nat1 Acad Sci USA 90, 1839–1842 (1993).
95. A. Mazumder, K. Raghavan, J. Weinstein, K. W. Kohn, and Y. Pommier, Inhibition of human immunodeficiency virus type-l integrase by curcumin. Biochem Pharmacol. 49(8), 1165–1170 (1995).
96. C. A. Janeway, The immune system evolved to discriminate infectious nonself from noninfectious self. Immunol Today 13, 11 (1992).
97. C. Natarajan and J. J. Bright, Curcumin inhibits experimental allergicencephalomyelitis by blocking IL-12 signaling through JAK-STAT pathway in T-cells and differentiation of neural antigen specific ThI cells. J Immunol 169, 6506 (2002).
98. H. C. Huang, T. R. Jan, and S. F. Yeh, Inhibitory effect of curcumin, an anti-inflammatory agent, on vascular smooth muscle cell proliferation. Eur J Pharmacol 221, 381–385 (1992).
99. M. Kitagawa, H. Mitsui, H. Nakamura, S. Yoshino, S. Miyakawa, N. Ochiai, M. Onobori, H. Suzuki, and T. Sumida, Differential regulation of rheumatoid synovial cell interleukin-12 production by tumor necrosis factor alpha and CD 40 signals. Arthritis Rheum 42, 1917–1926 (1999).
100. B. Bosman, Testing of lipoxygenase inhibitors, cycloxigenase inhibitors, drugs with immunomodulating properties and some reference antipsoriatic drugs in the modified mouse tail test, an animal model of psoriasis. Skin Pharmacol 7, 324–334 (1994).
101. M. C. Heng, M. K. Song, J. Harker, and M. K. Heng, Drug-induced suppression of phosphorylase kinase activity correlates with resolution of psoriasis as assessed by clinical, histological and immunohistochemical parameters. Br J Dermatol 143, 937–949 (2000).
102. A. Bernd, C. Theilig, S. Kippenberger, A. Ramirez-Bosca, M. Podda, J. Diaz, J. Miquel, and R. Kaufmann, An extract of Curcuma longa exerts anti-oxidative, anti-inflammatory and antiproliferative effects on human keratinocytes in vitro. J Invest Dermatol 109, 460–464 (1997).
103. A. Bernd, C. Theilig, S. Kippenberger, A. Ramirez-Bosca, J. Diaz, J. Miquel, and R. Kaufmann, Effect of Curcuma longa extract on the expression of proinflammatory cytokines. Skin Pharmacol App. Skin Physiol 13, 226–234 (2000).
104. I. Kurose, H. Higuchi, S. Kato, S. Miura, N. Watanabe, Y. Kamegaya, K. Tomita, M. Takaishi, Y. Haire, M. Fukuda, K. Mizukami, and H. Ishii, Oxidative stress on mitochondria and cell membrane of cultured rat hepatocytes and perfused liver exposed to ethanol. Gastroenterology 112, 1331–1343 (1997).
105. V. Rajakrishnan, P. Vishwanathan, K. N. Rajasekharan, G. Gunashekaran, and V. P. Menon, Role of curcumin in alcoholic hepatotoxicity. Med Sci Res 26, 715–719 (1998).
106. A. Helen, K. Krishnakumar, P. L. Vijayammal, and K. T. Augusti, Antioxidant effect of onion oil (Allium Cepa linn.) on the damages induced by nicotine in rats as compared to alpha-tocopherol. Toxicol Lett 116, 61–68 (2000).
107. D. Yildiz, N. Ercal, and D. W. Armstrong, Nicotine enantiomers and oxidative stress. Toxicology 130, 155–165 (1998).
108. C. Kalpana and V. P. Menon, Modulatory effects of curcumin on lipid peroxidation and antioxidant status during nicotine-induced toxicity. Pol J Pharmacol 56, 581–586 (2004).
109. K. Polasa, A. N. Naidu, I. Ravindranath, and K. Krishnaswamy, Inhibition of B(a)P induced strand breaks in presence of curcumin Mutat. Res 557, 203–213 (2004).
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2007 Springer
About this chapter
Cite this chapter
Menon, V.P., Sudheer, A.R. (2007). ANTIOXIDANT AND ANTI-INFLAMMATORY PROPERTIES OF CURCUMIN. In: Aggarwal, B.B., Surh, YJ., Shishodia, S. (eds) The Molecular Targets and Therapeutic Uses of Curcumin in Health and Disease. ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY, vol 595. Springer, Boston, MA. https://doi.org/10.1007/978-0-387-46401-5_3
Download citation
DOI: https://doi.org/10.1007/978-0-387-46401-5_3
Publisher Name: Springer, Boston, MA
Print ISBN: 978-0-387-46400-8
Online ISBN: 978-0-387-46401-5
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)